This article is more than 5 years old. Information may no longer be current.

ACR adds Vectra test to recommended RA activity measures

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American College of Rheumatology has added the Vectra blood test, developed by Myriad Genetics, to its list of recommended disease activity measures for rheumatoid arthritis, according to a press release.

“We are excited that the Vectra test has been included the ACR’s recommendations for disease activity measures,” Elena Hitraya, MD, PhD, chief medical officer for Myriad Autoimmune, said in the release. “It will provide physicians with an additional option to evaluate their patients with RA. Vectra objectively measures the inflammation associated with RA and can provide valuable information to help clinicians improve treatment decisions and outcomes for patients with RA.”

The ACR announced the recommendation in a special article published in Arthritis Care & Research. In the article, “2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures,” Vectra is one of 11 disease activity measures that met a minimum standard by categorizing disease activity states and being feasible for regular clinical use. According to Myriad, Vectra was one of the five most studied disease activity measures for RA. The company added that there are currently more than 35 peer-reviewed journal publications on Vectra.

According to Myriad, Vectra is a multibiomarker molecular blood test that provides an objective measure of inflammatory disease activity in patients with RA. Testing is performed at a Clinical Laboratory Improvement Amendments (CLIA) facility, and the results are reported to the physician within 5 to 7 days. Physicians can receive the results through fax or a private web portal.

 

The ACR has added the Vectra blood test, developed by Myriad Genetics, to its list of recommended disease activity measures for rheumatoid arthritis, according to a press release.

Source: Adobe

“Three out of four rheumatologists have used Vectra and have ordered more than 900,000 tests for their patients,” Myriad stated in the press release. “Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes.”